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IV - CONCLUSIONS I - INTRODUCTION AND METHODOLOGY 
The  treatment  or  improvement  of  pathological  conditions  each  severely 
affecting  a  small  part  of the  population,  and  without  satisfactory  solution, 
raises a number of delicate questions  that neither modern  society,  the public 
health  authorities,  or the health  research  industry can  afford to  ignore,  or to 
treat superficially. 
The  European  Commission,  perfectly  aware  of this,  is  proposing  a  wide 
consultation  with  the  objective of defining  and  setting  up,  after  finding  the 
means, an aggressive and effective health policy. 
This  particular  study,  which  it has  requested,  submits  for  reflection  by  the 
interested  parties  of  the  European  Union,  a  set  of  points  that  need 
consideration.  It is based on analysis of existing regulations, principally in the 
U.S. and Japan, and their effects, on various manifestations of interest, both at 
community level in  the European countries and others, and on an  examination 
of numerous publications. 
The W.H.O., the pharmaceutical industry associations in Europe, the U.S. and 
Japan,  individual  firms  or groups  of firms,  as  well  as  patients  associations, 
have kindly communicated their experiences in this area. 
ll - DEFINITIONS & OBJECTIVES 
A  Definitions and Review of the Situation 
It is generally considered that a rare disease is one that does not strike more 
than  650  to  1000  people  per  million.  The  W.H.O.  appear  to  have 
identified about 5,000, of which 4,000 seem to be linked to genetic factors. 
Many  of these  do  not  benefit  from  any  support  or aid,  institutional  or 
scientific,  and  are  considered  as  orphans.  Their  symptomatic  or  causal 
treatment or better still, their prevention implies the need for a much deeper 
knowledge of the origin and  the effects of the disease,  as  well as  a search 
for "tools", medicinal, diagnostic and surgical. 
Unfortunately such research is extremely onerous and risky,in the sense that 
the chances of success are very limited,  and in  addition,  it comes within a 
domain which is to a great extent provided by the private sector. 
-2-It  is also not accessible to charitable organisations, or  patient associations that 
nevertheless ask for it. The cost, the difficulties, the heavy responsibilities, 
the pressures moral and public, the absence of foreseeable profit etc,  ... are 
all elements ~at  do not really prompt industrial or scientific sponsors to give 
much consideration. 
Their inevitable lack of interest, even the withdrawal of the development of 
certain potential drugs have led to the idea of "otphan" drugs, in the same 
way as "otphan diseases" implies severe pathological conditions, either rare 
or affecting only a small portion of  the population, or only spread among the 
poorest populations. It is as much the more fundamental research into these 
diseases and their causes(s),  as  on more specific research into treatments ( 
medical  or  otherwise),  or fmally  on  the  development  with  a  view  to 
marketing of existing potential therapies that must be examined. 
The frrst seems to be more the privileges of societies and public institutions 
within their research programmes, whilst the following ones are essentially 
the responsibility of industry,  especially pharmaceutical.  But the latter is 
subject to profitability restraints from which there is no escape. However one 
must admit that public institutions are more and more confronted with the 
same problems. 
The W.H.O.  devotes  special attention to  those  diseases  where  no  useful 
treatment exists and  also  to  Tropical Diseases,  which are  not necessarily 
rare,  but  can  be  regarded  as  otphan  diseases,  since  they  tend  to  be 
"abandoned" because of the extreme poverty of those countries and affected 
populations,  and  of the  dramatically  insufficient  medical  infrastructure 
{Tropical  Disease  Research  Programme).  The W.H.O.  acts  through  its 
regional offices and health ministries, but it also collaborates with numerous 
institutions, international and other organisations interested in health , non-
government organisations and industry. Towards the latter it operates,  to a 
great extent,  through individual contacts with voluntary firms,  known for 
their traditional interest in such research or their therapeutic "palette" in the 
matter.It offers its expertise in the area of those diseases as well as technical 
aid. Equally available is information on treatments used for those sick people 
who, whilst staying in the affected regions,  contract a  "Rare in the West" 
disease. 
It also  collaborated  with  the  World  Bank  which  published  in  1993,  an 
interesting report on "World Development". 
With that in mind and in the setting of infectious or viral diseases, the case 
of vaccines merits special attention. 
Incentive and support of R & D appears to be a moral obligation and a duty 
on the part of the Public Health Authorities. 
More specifically regarding the drug (principal object of the present study) 
such an incentive should or could cling to the pursuit of objectives in the 
-3-most balanced possible way. 
Everything leads to the belief that industry, as far as it is concerned, would 
bring its collaboration as well to seeking means, as to setting them up and 
exploiting them. 
B  Objectives 
•  An humanitarian obiective : 
by stimulating the interest of researchers and sponsors 





R &  D of new curative/preventive drugs 
development  or possible  exploitation  of secondary  properties  or 
indications of known drugs 
marketing/re-marketing of existing or abandoned drugs 
by ensuring their supply in sufficient quantities 
by preventing any increase of the frequency of the disease 
by informing beneficiaries and sick people of the existence and potential 
of certain drugs 
by ensuring their quick availability to those who need them 
•  A scientific objective 
by  stimulating  the  development  of knowledge  on  rare  diseases,  their 
cause(s) and possible treatments 
by specifying the epidemiological data,  namely by establishing registers 
identifying rare diseases,  their frequency, their extension or regression, 
by ensuring an appropriate classification 
by identifying, with the possible assistance of  Universities and Academies, 
those linked to genetic factors,  allowing a pre- or post-natal diagnostic, 
a  surgical  treatment  or  a  possible  genetic  therapy  (pre-competitive 
research) 
by envisaging the creation of centres of specific excellence (for selected 
-4-diseases) 
•  an economic objective : direct or indirect 
by  proposing  measures  likely  to  boost  the  interest  in Europe  of the 
international Phannaceutical Industry, as well as small and medium sized 
entetprises, thus increasing competition. 
The global increase of knowledge, the development of biotechnologies, the 
analysis of the human genom, open new opportunities. 
As regards the Phannaceutical Industry, where the moral satisfaction that can 
often be achieved by free availability of essential products already procurable 
can  be  considered  a  duty,  could  invest  - more  reasonably  - in  their 
development and benefit in this respect from a more positive brand image. 
ill THEMEANS 
A  General Points 
Judging by the steps that have already been taken in various countries,  in 
particular in the United States and in Japan (see details infra), by the many 
analyses and comments available, it seems that the means envisaged (and that 
can be envisaged today)  are  all in the  framework  of a  few  fundamental 
concepts, very limited in numbers.  And it is really the balance necessary to 
their materialisation that is the problem. 





that without participation of the private Pharmaceutical Industry, R 
& D of (new) drugs remains totally insufficient, if not impossible. 
that if the latter, for reasons of humanity and/or prestige, is ready to 
make available free of charge certain drugs in its possession - under 
conditions remaining reasonable - it cannot ensure alone an intensive 
R & D, particularly expensive, with particularly high risks (difficulty 
of appreciation) and without any hope whatsoever of profitability at 
the end,  while taking  on greater and greater legal responsibilities 
(linked to making the drug available); 
that  as  a  consequence,  a  close  collaboration  between  responsible 
Authorities and research Industry should be set up; 
that this collaboration should extend to patient associations the role of 
which is essential (e.g. information); 
-5-*  that this collaboration implies : 
for public services : 
the set up of fmancial, fiscal,  scientific, regulatory incentives; 
the acceptance of one end or the other infonnation (see infra); 
the reinforcement of the collaboration with academical institutions 
through fmancial assistance to fundamental research; 
for industry : 
the  suggestion  of adequate  research  programmes,  their pursuit  in 
consultation with the responsible Authority,  the supply of possible 
products  with  the  relevant  information,  even  in the absence  of a 
proper commercial profitability from the moment it accepts to take 
advantage of various incentives made available. 
that  the  prime  objective  of  Public  Health  protection  suffers  no 
infringement to the  quality  of evaluation of the dossier  submitted  for 
approval. 
The expression in regulatory tenns of these great principles is to be found more or 
less developed, in the various legislation presently in force. 
B  In the United States 
General Review 
The Orphan Drug Act of  4.01.83 defmes the objectives and main principles. 
As early as October 1984, it sets the conditions and limitations, envisaging 
clinical and pre-clinical experimentation,  the designation  to the  status  of 
"orphan drug", the protection granted to these products and the need for an 
early availability for some patients.  Antibiotics and biological products are 
considered  in this  legislation and  the  "orphan disease"  is  defmed  as  and 
illness affecting not more than 200.000 people in the United States. 
In October 1985, a new amendment modified the approval conditions and a 
few later clarifications dealt with designation and subsidies. 
Meanwhile, the FDA in collaboration with other government services, while 
preparing the application regulations, proposed- via the Office of Orphan 
Products Development (OPD), guidelines informing the applicants of the 
conditions for obtaining the designation of "Orphan Drug" and on· assistance 
protocols.  The available subsidies  and tenns of the request are published 
annually. 
-6-Very  recently  (on  29.12.1992),  further  to  a  request  from  the  American 
Congress and after a wide consultation,  the Food &  Drug Administration 
(FDA) published,  together with its interpretation,  the modifications to the 
Orphan  Drug  Act  and  the  procedures  to  be  applied,  under  the  title  of 
"Orphan Drug Regulations : Final Rule. 
This very detailed document is  the more interesting in that it is  based on 
some 8 years of experience and that it justifies the selected options. 
In other words, it never tries to divert from the objectives sought early on in 
the legislation, i.e.  give Industry sufficient incentives to promote R & D for 
new  products  (or  the  utilisation  of properties  or side  effects  of known 
substances)  and  give  the  patients,  as  quickly  as ·possible,  access  to  the 
potential treatment needed,  while avoiding deviations such as laxity in the 
analysis of  the benefit/risk connection, or undue profits or advantages for the 
Industry,  or even  utilisation  of the  legislation  as  blocking  instrument  to 
competition or scientific progress. 
It must be noted that the FDA gives no consideration as to the price of the 
fmally  authorised  drug;  only  the  marketing  authorisation  (MA),  its 
preliminary work and conditions falling within its competence. 
In brief, this document comprises 6 chapters : 
a.  General Points : 
Fields  of application  :  establish  standards  and  procedures  concerning 
experimentation, the designation,  the exclusivity period, the availability 
before marketing. 
Defmition  of  terms  used  :  particularly  the  concepts  of  "clinical 
superiority" and the character of "novelty". 
b.  Recommendations 
of the FDA- written or not- for experimentation (assistance protocols). 
c.  Eligibility 
to  the  status  of "Orphan  Drug".  It is  to  be noted  that  the  "Orphan 
Medical  Devices"  or the  "medical  food"  are  not  concerned  by  this 
legislation.  All drugs are, including biological ones : 







The product  should  however  not  be  reserved  exclusively  for  the 
treatment of the rare disease.  It can concern the exploitation of a 
property, even of only a side effect of a commercialised product, or 
of the study for other indications. 
The disease cannot affect more than 200.000 people in the U.S. (or 
the product cannot be administered to more than 200.000 people in 
the U.S. - vaccines for instance). 
A product which is intended for more than 200.000 patients is also 
eligible if  it cannot be reasonably expected that its commercial results 
cover the costs of the R & D for the indication studied. 
Control of the data on the frequency  (prevalence) of the disease,  or 
on  the  presumed  non-profitability  (with  possible  data  on  the 
justification of costs involved outside the U.S.). 
The applicant must be - or have as an agent - a pennanent resident in 
the  U.S..  The  request  may,  or  not,  precede  the  Marketing 
Authorisation. 
Conditions for refusal, modification, transfer to another sponsor, of 
publication or dismissal of status.  To be noted that an increase of the 
frequency of the disease does not lead to the dismissal of the status 
nor of the advantages linked to it, if  the data was valid at the time of 
designation. 
d.  Exclusive awroval 
The FDA will not grant any Marketing Authorisation for the same product 
during 7 years dating from the product receiving the status of "Orphan 
Drug" to a product, except 
in case of agreement from the holder 
in case of revocation of status according to previous criteria 
in case of suppression of the MA 
in case of incapacity by the holder to supply the product in sufficient 
quantities. 
The FDA infonns the sponsor and the public by a list updated regularly 
with names and particulars of the holder of the recognised product. 
e.  Access to treatment 
Besides the measures in case of insufficient supplies (temporary or fmal), 
an earlier "opening" of the access to the product by the patient is planned 
(by allowing him to receive the drug under investigation as  a treatment 
and not for the purpose of research). 
-8-f.  Infonnation 
Publication  of the  list  {updated  monthly)  of authorised  products  and 
availability of additional infonnation (to  be detennined by the FDA). 
However,  the FDA will  refuse  to  give any  confidential or premature 
information. 
It has also to be remembered that 
upon  obtaining  the  status  of "Orphan  Drug"  a  tax  credit  of 50%  is 
obtained on the cost of clinical trials made in the U.S; 
subsidies for conducting clinical experimentation can be requested  (the 
available amounts are published annually - as an example they amounted 
to 12  million dollars in 1995).  Clinical trials in phase 1,2 and 3 can 
expect subsidies up to $ 100.000 per annum for a maximum of 3 years, 
while trials in phase 2  and  3 could receive up to  $  200.000 during  a 
maximum of 2 years; 
and that no evaluation of environmental risk, presumptively considered as 
insignificant, is required; 
The exemption of registration fees could, according to the FDA, be the 
subject of a later discussion. 
Additional comments 
It  cannot be denied, even if  the summary above is particularly short, that the 
legislation  in  question  is  very  closely  studied  and  aims  to  reach  the 
determined objective (meeting a duty  of state and of human nature) without 
calling upon a  forced  and unrealistic  voluntary action,  associating public 
effort and private effort, encouraging the latter significantly, but marking out 
the  ways  open  to  Industry  for  ethic,  moderation,  scientific  progress, 
competition in the sector and in the different segments of the sector, to be 
preserved. 
Already, prior to the Orphan Drug Regulation of 1993, which codified the 
procedures and practices of the Orphan Drug Act, applied by the FDA, 
results  were not long in coming.  According to the FDA, the stimulating 
combination of 7 years exclusivity, subsidies to research and tax credits, has 
lead to the development of new products by numerous small enterprises and 
while, before the signing of the law, two or three drugs a year could have 
been eligible to the title of "Orphan Drug"  ,  an average of eight a year, 
approved and marketed,  have been counted  since  1984 (  48  drugs  for 58 
diseases mentioned by the FDA on 28.01.91). 
-9-In  March  1993,  according  to  a  publication  of  the  Pharmaceutical 
Manufacturers Association in collaboration with the FDA's Office of Orphan 
Products Development, 488 designations to the status of Orphan Drug, 64 
drugs approved and 189 drugs in development for a total of 132 sponsors 
were counted.End  1994,  682  designations  were  registered  of which  110 
products approved. 
However,  voices  have  begun  to  rise,  denouncing  the  profit,  excessive 
according to them, that the Pharmaceutical Industry would or could draw in 
certain cases of this legislation.  Amendment proposals have been presented 
both to the Chamber and the Senate.  They aim to : 
*  in principle reduce from 7 to 4 years, the exclusivity period granted; 
*  grant 3 additional years to products with a limited commercial potential 
(to be defmed); 
*  make sure the frequency  cannot exceed  200.000 patients during  the 3 
years following the application (or otherwise allow the approval of other 
products). 
These amendments should, once accepted, have been published and in force 
before the  end  of 1994.  But  so  far  no  modification of the law  in that 
direction has taken place or is planned at short term. 
The  Phannaceutical  Industry,  or  at  least  certain  segments  of it,  have 
denounced  the  flaws  or incoherences  which  have  appeared,  such  as  : 
differentiation  criteria,  especially  for  the  macromolecules  for  which  the 
"chemical identity" cannot suffice on its own to grant or not a character of 
novelty,  or also  the concept of "clinical superiority"  which remains  very 
subject to interpretation, or fmally the sometimes ambiguous relation between 
patent and exclusivity. 
C  In Japan 
General Review 
As early as 29.06.1985, a circular from the Bureau ofPhannaceutical Affairs 
defmed the concept of "Orphan Drug"  and the nature of the dossier to be 
supplied to obtain a Marketing Authorisation.  This circular comprised four 
sections : 
-10-a.  Object: 
To  promote  the  development  of drugs  intended  for  the  treatment  of 
diseases  affecting only a very limited number of people in Japan,  but 
essential for their treatment, by proposing a simplified list of documents 
to be submitted to support the request. 
b.  Defmition : 
The recognition of status  of "Orphan Drug"  and  the  obtention of the 




a very low rate of frequency of the disease for which the drug would 
be indicated; 
no treatment must exist; 
it must  be possible  to  grant  the  authorisation  quickly,  given  the 
particular importance for the sick person. 
c.  Dossier 




Data on the number of sufferers in Japan, on existing treatments, the 
possible usage of the drug abroad  ... 
The clinical ftle will have to content itself with the results of trials 
achieved in Japan next to any clinical data obtained from abroad (in 
accordance with the recommendations from  the Bureau of Clinical 
Affairs). 
The results on stability studies can be submitted later on. 
d.  condition after marketin&  : 
Obligation to supply any  information to users  on the efficacy and the 
tolerance. Obligation also to take all possible steps to collect a maximum 
of information on usage. 
Additional comments 
It would appear that these measures,  which in fact only set out to alleviate 
the dossier in order to achieve an easier and faster availability of the product 
to the patient, have not obtained the result expected. 
-11-The authorities then considered an important recasting  of the law of 1979 
to which,  on 1.10.1993 important modifications have been suggested,  in 
order to  "better promote",  "to adopt a more aggressive support policy for 
"Orphan Drugs". 
From now on the Ministry· of  Health and Welfare  (MHW), in consultation 
with the Central Pharmaceutical Affairs Council (CPAC) will be allowed to 
grant the status of "Orphan Drug" when the product - whether a new product 
or a new indication - appears to be of great value in case of usage and that 
less than 50.000 patients are affected in Japan. 
The decision will be published, as well as the particulars of the sponsor and 
the target indication. 
Once this  status  is granted,  the  "Drug Fund for Side Effects Relief and 
Research Promotion" (Drug Foundations) will bring its fmancial assistance 
for R &  D, as well as technical advice to fmns. The latter will also benefit 
from a tax relief (6%) on R &  D  expenses  (except those fmanced by the 
Fund) and a maximum of 10% reduction on the tax rate of the fmn, as well 
as an extension of the re-examination period which, presently from 4 to 6 
years,  will  extend  up  to  10  years.  The  modifications  of the  taw  also 
anticipate an accelerated procedure for the Marketing Authorisation and a 
reduction of the dossier content. 
(Flow-Chart of the proposed system in annex). 
The status can be withdrawn if: 
*  the number of patients in Japan exceed 50.000; 
*  the  medical  need  regresses  (availability  of  another  treatment,  for 
example); 
*  the experimentation is not carried out; 
*  or if the holder infringes the law. 
The "Drug Foundation" will receive funds from the Government and from 
beneficiaries of subsidies, as soon as the latter will have made profits from 
their orphan drugs. 
The Pharmaceutical Industry has presented the Bureau of Pharmaceutical 
Affairs with a petition entitled "Needs to clarify the requirements relative to 
the designation of Orphan Drugs and measures to be taken concerning these 
products". 
-12-The JPMA (Japanese Phannaceutical Manufacturers Association) : 
*  requests that the status of Orphan Drug be recognised for any product 
meeting the criteria defmed and for which an application has been ftled 
by a finn; 
*  considers a global donation from  Industry as participation to the supply 
of starting subsidies; 
*  is opposed to the proposal of a 3% tax for "Orphan Drug Companies" on 
the turnover exceeding 1 billion Yens/year during 10 years; 
*  considers as acceptable the payment of 1 % of sales over 100 million Yens 
per year,  until the time when  the government subsidy  will have been 
repaid; 
*  expects in return tax relief, priority in the examination of dossiers and a 
liberal approach to questions on subsidies, price and reimbursement. 
It is premature to give a verdict on the results of the implementation of these 
measures. There was mention of 15 drugs having obtained their status since 
1987, but it appears from a frrst investigation that these measures essentially 
aim  at  rationalising,  simplifying  and  accelerating  the  procedures  while 
safeguarding,  as  much as possible,  the quality,  efficacy and safety of the 
product.  On the other hand,  the  "incentives"  for  industry  are  modest, 
precarious and temporary and result much more in allowing financially  the 
industrial effort that instigate or promote it. 
However, since the revision of the law,  69 products provided by 50 ftnns 
appear to have received the status of orphan drug.  On the other hand, the 
MHW has proposed, for 1994, the availability of subsidies to an amount of 
about 4 million dollars. 
D  Elsewhere 
General Review 
There seems to be no regulatory measures to draw the attention. However it 
cannot be denied that there is  concern everywhere on the matter.  As  an 
example: 
In Singapore : the authorities and the Pharmaceutical Industry have agreed 
on a basic programme. 
-13-E  In Europe 
General Review 
No specific legislation has been set up nor, to date, even proposed. In some 
(large) countries, a precise mention is introduced in the official texts. 
a.  In France : 
The Law of 8.12.1992 modifying  book V  of the Public Health Code 
relative to the Pharmacy and drug, article 21, provides for the exceptional 






are intended for treatment of severe pathologies, while no alternative 
therapy exists, if  their efficacy is strongly presumed in view of the 
results  of  therapeutic  trials  which  they  have  undergone  for  a 
marketing authorisation application (compassionate use); 
are  intended for patients  affected by rare diseases  and if no  drug 
already authorised in the sense of article L.601 and likely to act as a 
substitute (orphan drugs) 
the  use  of these  drugs  is  authorised,  for  a  limited  time,  by  the 
Minister in charge of Health, with prior agreement of the holder of 
the drug' exploitation right in the case outlined in the frrst paragraph 
of this article.  This authorisation can be suspended or withdrawn if 
the  conditions  outlined  in  this  article  are  no  longer  met,  or for 
reasons of public health. 
The  Decree  94-568  defmes  the  granting,  renewal,  suspension  and 
withdrawal from temporary use conditions for these drugs. 
Defmition,  Classification,  Prevalence  deserve  to  be  specified.  For 
instance, it has been suggested to make the follo~ing modifications : 
Omhan  Drugs  :  are  intended  to  diagnose,  prevent,  treat  severe 
pathologies, without it being reasonably possible to absorb the  costs of 
development and distribution,  as long as their efficacy ..... 
Drugs possessing omhan indications  : are  drugs  already registered but 
whose usage has  shown the therapeutic interest in other rare or severe 
pathologies,  at different  dosage  than  those  registered  and  when  there 
exists no therapeutic alternatives. 
-14-In other words, the suspicion of an orphan indication can derive from an 
"extensive"  usage  of a  drug,  through  a  step-by-step  approach  by  the 
physician, in non-registered indications because they were not supported 
by a sufficiently structured experimentation.  The latter must be promoted 
and supported, if  indicators flicker .seriously. 
On the other hand, a very recent law (11th January 1995), modifying the 
list  of  specialities  subject  to  reimbursement  to  social  beneficiaries, 
confmns the intention of the French Authorities to set a procedure for 
"exceptional drugs", and underlines the absence of documented clinical 
studies specific to "orphan indications". 
In this particular case, the purpose is certainly not to promote R & D, nor 
even marketing of drugs for orphan diseases,  but only allow access of a 
particular product to patients suffering from an orphan disease. The point 
is to give a socio-economic follow-up to the "authorisation for exceptional 
use of a  drug in a  non registered indication",  according to the above 
mentioned law. 
Let us  indicate here that research organisations  such as INSERM,  the 
CNRS and others have set up infonnation and training activities and also 
act somewhat like "opinion promoters" in favour of a greater activity in 
the area of rare diseases. 
b.  In Spain : 
Article 34 of the law 25/1990 of 20.12.1990 on drugs considers that the 
Government can adopt special measures in relation to their manufacture, 
their economic, fiscal, distribution and release regime, concerning "drugs 
without any commercial interest". 
c.  In the United Kingdom : 
In the field of  research, there is a defmite collaboration between academic 
authorities and industry; in particular, the Medical Research Council and 
some industries work on programmes (diseases in developing countries). 
In some particular cases, requirements before Marketing Authorisation are 
limited subject to commercialisation for low populations and availability 
of further data. 
d.  In Gennany: 
In  1990,  Parliament,  supported  by  the  BPI  (Bundesverband  der 
Pharmazeutische Industrie) proposed to the Federal Government that the 
possibilities for promoting R  & D of orphan drugs be  studied and that 
consecutive measures  be implemented without delay.  Parliament also 
requested the problem be taken to European level. 
-15-In 1993, the Health Minister invited the Industry to a new discussion but 
this concentrated on the question of  antidotes in case of  intoxication, given 
the withdrawal of some of them for economic reasons. 
e.  Elsewhere 
The Nordic  Council proposed,  in  1985,  a programme with a view  to 
collecting  some  information  on  rare  diseases  and  the  patients  groups 
suffering from rare diseases in Scandinavia. 
In Denmark, the Health Minister has founded a research centre for rare 
diseases  and  handicapped people.  In addition,  in December 1993,  the 
National  Health  Council  suggested  an  appropriate  organisation  for 
hospitals (diagnosis and treatment).  Bearing in mind the low incidence, 
only two centres were recommended to be established.  One of them, the 
Centre  for  Rare  Disorders  and  Disabilities,  was  created  in December 
1994,  in association  with  the  Department  of Pediatry  at  the  hospital 
concerned. The other is planned for 1995. 
In Sweden,  the  status  of orphan  drug  does  not exist but a particular 
procedure is open for drugs of great medical value for which the sales 
forecast is low. 
The Apoteksbolaget, which administers some 800 pharmacies, provides 
the manufacture and the distribution (through a few  specialised units) of 
non-commercialised orphan drugs.  It takes on if  necessary,  the galenic 
formulation,  takes  care  of  documentation  and  organises  R  &  D 
programmes  in collaboration  with  the  doctors.  In 1990  the  Swedish 
Medical Products  Agency  suggested  a  policy  for  orphan drugs  to  the 
Government and to the Phannaceutical Industry which to date remains 
without concrete follow-up. 
But it is in Sweden that an interesting initiative has been launched by a 
few pharmaceutical fmns, i.e. the creation in 1988 of "Swedish Orphan 
AB". Its mission is described as follows : 
"To provide patients, healthcare personnel and the pharmaceutical industry 
with  an independent  global  network,  specialising  in the  development, 
marketing and distribution of Orphan products for the treatment of rare 
disorders" 
An international  "Orphan"  network  has  been  set  up  (associations  in 
Sweden,  Denmark,  Finland,  Norway,  France,  United  States,  Japan, 
Australia)  and  some  contacts  established  with  more  than  20  different 
pharmaceutical fmns and associations. 
-16-Through this network, which is oriented towards certain therapeutic areas, 
clinical experimentations  have  been  carried  out as  well  as  actions  of 
marketing,  advice  and  support  for  the  obtention  of  a  Marketing 
Authorisation. 
f.  At Communicy level (Within the European Union) : 
Although  the  Union  is  not  yet  equipped  with  any  specific legislation 
concerning  Orphan  Drugs,  it  is  certainly  not  from  unawareness  or 
disinterest,  but because  of "helplessness"  in  front  of administrative, 
political,  and  economic  barriers,  consequent upon the  division  of the 
Unions's territory. 
Now that the internal market for drugs is becoming a reality, and a unique 
marketing authorisation is instituted, nothing whatsoever justifies such a 
gap in the European Union, neither from an ethical point of  view nor even 
from an economic point of view.  The size of the population not only 
justifies  it,  but even  requires  it;  the  centralised  system  of Marketing 
Authorisation allows it so  well at the level of granting the authorisation 
as on that of dialogue and technical support; the R &  D programmes are 
thinking  about  it  and  must  become  concrete  and  develop  and  the 
intellectual and industrial protection is virtually harmonised. 
The fact remains of course that any subsidy or possible fiscal incentives, 
should avoid the traps of  discrimination between countries.  Furthennore -
and  it is  very  important  -the  risk  that  national  systems  of price  and 
reimbursement  fiXing  in  some  Member  States  compromise  the  fmal 
economic balance sheet. 
However that may be, the European Union for drugs lives nowadays to 
the rhythm of a very sophisticated legislation applied to any drug and in 
which is found, here and there,  some allusion to a possible exemption-
but always  subject  to  interpretation  - to  the  prescriptions  of nonnal 
procedures. 
It is not possible to talk of "incentive" toR &  Din this matter, on the 
contrary the few  "alleviations" of the requirements that can be hoped for 
according to Directive 91-507 are far too uncertain and too late in the 
development process.  They  cannot  on their own persuade  a  finn  to 
launch itself, in this difficult adventure of  developing a drug for an orphan 
disease, if  it does not itself have sufficient means.  In any case, it is an 
adaptation  to  the  epidemiological  and scientific  reality  that  has  to  be 
envisaged, maybe even case by case. 
-17-Since 1987, and considering that an otphan drug represents a significant 
interest in the therapeutic field, the procedure known as "concertation" is 
accessible  to  it.  It would  appear  to  be the  same  for a  new  way  of 
administration, considered as innovative, of a known drug, but, being a 
new  indication,  it would be the same only if  the therapeutic interest it 
represents is know.  The conditions of access to the centralised procedure 
which took effect on 1.01.1995 being identical, this reflection is worth 
mentioning. In any case, the admissibility decision being in the hands of 
the  Committee  of  Proprietary  Medicinal  Products  (CPMP),  an 
"uncertainty"  remains ... that  precise  criteria  as  to  the  designation  of 
"otphan drug" remove. 
The draft regulation on fees  collected by the European Agency for the 
Evaluation of  Medicines authorises, in its article 6, the suppression of the 
fee (possibly partial and only on the advice of the Director assisted by the 
Committee of  Proprietary Medicinal Products).  However appreciated this 
initiative may be, it remains  completely insignificant in relation to the 
investments made, and  moreover only affects the cost of marketing of the 
result of a research having ended up in the development of a marketable 
drug, and cannot be considered as an incentive toR & D, but at the most, 
an incentive to the decision of marketing a drug of which the fmn would 
have successfully fmalised the development prior to marketing. 
For any  new  drug,  authorised  by  the centralised procedure,there also 
exists a protection of data spread over 10 years.  This protection would 
of course apply to  otphan drugs  should  a Marketing  Authorisation be 
applied for and obtained through this procedure. Although this protection 
is essential, it can however not be compared to a market exclusivity such 
as granted and used in the United States for a non-patent drug.  On the 
other hand it should be firmly guaranteed for all the data in support of a 
new indication of an existing product. 
Whatever the case may be, the first question is to be capable of fmancing 
and proceeding to the R & D of the drug and thus it is at a much earlier 
stage than the MA, that action must be taken, i.e. fmd, propose and make 
available sufficient fmancial  incentives.  International fmns as  well as 
small and medium entetprises should have access to it and the quality of 
development (in biotechnology, for instance) should be supported, mainly 
with the latter. 
Indeed, as  mentioned above,  directive 91/507 of 19.07.1991 modifying 
the annex  to  directive  75/318  allows  for  exemptions  to  the necessary 
documentation  to  support  demands  relative  to  the  efficacy  and 
harmlessness,  if the  indications  considered  appear  so  rarely  that  the 
applicant cannot reasonably be requested to supply complete information 
(i.e. an adaptation of the requirements to what is reasonably possible). 
-18-However it is a text which is very much subject to interpretation.  The 
dialogue  which  should  start  between the applicants  and  the European 
Medicines  Agency  well  before  entering  the  dossier  of  marketing 
authorisation application, would at last, allow this text to be used to the 
full as long as it ends up in precise commitments. 
The heavy  responsibilities  lying  on the  fmns aggravated  by  the  legal 
uncertainty cannot be forgotten.  They are likely to lead a fmn to abandon 
the marketing of a drug which was unable or could not- in the present 
state  of  know  ledge  - meet  the  usual  standard  of  safety  and 
phannacovigilance. 
Within the scope of a more fundamental research on orphan drugs, there 
is  also  a  Community  interest  in  Research  Programmes  partially 
subsidised.  In this way the recent programme Biomedicine and Health, 
in its chapter 4  :  "socio-economic impact", mentions by name in point 
4.6: rare diseases, and in the phannaceutical research concerning clinical 
experimentation it mentions : "including an inventory of  rare diseases, and 
a register of so-called "rare" drugs. 
The  Biotechnological  programme  can  also  have  an  influence  on  the 
matter. 
On the other hand, a Workshop on "European Clinical -Trial Network", 
organised  by  the  Commission  in  November  1992  took  note  of the 
difficulties,  (among others,  recruitment of patients),  of a valid clinical 
study for such products and identified the absence of fmancing as one of 
the main barriers. 
Finally, the "Groupe de Conseillers pour l'Ethique de Ia Biotechnologie" 
mentions in 1994 :  "According to this equal access principle, a special 
status could be attributed at European Level to orphan drugs and diseases 
(as already done within the Biomedical and Health Research Programme 
of the European Commission)". 
g.  Patient Associations. 
Patients and parents of victims, faced as they are with the difficulties and 
hesitations of industry, beneficiaries etc, have created or participated in, 
patient associations, foundations and charitable organisations in order to 
take advantage of appropriate treatments for their disease.  At the same 
time as  requesting better attention to the needs  and rights of patients, 
affected  by  rare  and  severe  pathologies,  by  way  of adequate  support 
measures from political authorities, they try to give active collaboration 
to the improvement of treatment and care. 
-19-To this effect, they make the most of existing products by intervening, if 
possible,  in  facilitating  their availability  and  use.  They  also  seek  the 
development of excellence centres and infmnation centres. In the United 
States,  NORD  (National Organisation for Rare Disorders)  collaborates 
closely  with  the  Office of Orphan Products Development,  and  has  an 
important data base available. 
In Europe, very many national associations exist, directed towards one or 
several particular pathologies. But a grouping at European level, or at the 
level  of  specificity,  does  not  yet  exist,  although  some  moves  to 
collaboration between them are appearing (example:  European Alliance 
of Genetic Support Groups in the Netherlands). 
This  does  not prevent some  of them  being very  active and  willing to 
collaborate.  The importance of the privileged contact they  enjoy  with 
patients and their families,  must not be underestimated. 
During a conference in 1991, organised  by RTMDC (Research Trust for 
Metabolic Disorders in Children), problems encountered in the usage of 
non  commercialised  drugs  were  clearly  identified,  namely:  source  of 
supplies, purity, phannaceutical formulation, toxicity testing, monitoring 
and legal issues amongst others. 
As a consequence, one of the speakers at this conference suggested that, 
an "Administration" of orphan drugs was  something to be envisaged. 
F. Vaccines 
As stated above, the interest of vaccines in many tropical diseases considered 
as orphan has not escaped the attention of the WHO. It  is in the framework 
of the Children Vaccine Initiative Task Force "Relations with Development 
Collaborators" which included industrialists, that a categorisation of vaccines 
has  been proposed.  It says  :  "New  vaccines,  whose  use is  likely  to  be 
restricted  to  developing  countries  what  might  have  tenned  "Orphan 
Vaccines".  Such vaccines, if  adopted as  CVI targets  are likely to require 
heavy donor support".  In the United States,  still within the scope of the 
CVI: "Achieving the vision" 1993, the committee recommends that an entity, 
tentatively  called  "National  Vaccine  Authority"  (NV  A)  be  organised  to 
advance the development, production and procurement of  limited commercial 
potential but of important Public Healthneed. 
-20-A reminder here of firstly : 
the importance of the European  Industry  in the vaccine industry  and  its 
dominant involvement in the supply to developing countries; 
and secondly : 
that this industry has, on several occasions, fulfilled its mission of  preventive 
protection  in  Public  Health  by  supplying  vaccines  or  serums  against 
infectious  rare and  severe  diseases,  with  no  hope  of fmancial  return  on 
investment  (examples  are  :  vaccine  against  brucellosis  of mediterranean 
shepherds, vaccine against leptospirosis of sewage workers... to name only 
two). 
IV CONCLUSIONS 
If  the economic impact on Society of rare diseases as a whole deserves a serious 
analysis and probably justifies the investment of public funds to get to better 
know and treat them, the moral obligation to seek appropriate treatments and 
means of  prevention is unanimously recognised as well as the absolute necessity 
to lead Industry in this direction. 
It  is thus only the means that need to be investigated. 
But  the  magnitude  of  difficulties  encountered  - scientific,  experimental, 
fmancial, ethical - linked most of the time as well to the lack of know  ledge as 
to the rarity of the disease and to the risk inherent to any new medication, does 
not allow to be satisfied with timid measures.  The research effort is enormous 
and  particularly  delicate,  because  it would  not be tolerable  that  these  rare 
patients be treated, without the quality of the drug and its harmlessness having 
been reasonably appraised.  In addition there is the risk of failure that must be 
kept in mind and which, already determining the orientation of research in view 
of drugs potentially interesting economically, which has here a new dimension 
in the absence of any hope of profitability. 
On the other hand, present technological developments open opportunities never 
equalled before.  Admitting that some 4/5th of rare diseases  have a  genetic 
origin,  biotechnology  and  analysis  of the  human  genom,  to  give  but  one 
example, will revolutionise the perspectives and offer major assets. 
But the interweaving of humanitarian, social, economic, industrial and scientific 
objectives  demands the intetpretation of the usual notions of risks (sanitary and 
fmancial), cost (global on healthcare), profitability (recovery of the investment 
whether successful or not, and legitimate profitability) and of responsibility (of 
the authorities, the investigator and the industrialist). 
-21-In other words, the thing to do is to consider a health policy completely specific 
and sustainable for the different actors. 
The success of measures taken in the United States allows to consider that they 
have enabled a true social advance. 
The exacerbated fear of some of too great a  n generosity" towards the Industry 
should not lead to the amputation of their beneficial effects while trying to avoid 
perverse effects (real or estimated). 
Japan,  through the application of a somewhat different philosophy, is in tum 
trying to reinforce the tendency by somewhat easing the load on the Industry of 
part of the fmancial investment which is absolutely too heavy and too long. 
Alone among the regions most advanced in phannaceutical R &  D, Europe has 
to date remained silent.  The importance and the quality of its Phannaceutical 
Industry would make inexcusable the maintenance of a passive attitude.  It is 
now responsible, in the field of  Public Health, for a population of more than 370 
million inhabitants, which is markedly more than the United States and Japan. 
That this responsibility be shared with the Member States should no longer be 
a constraint, at least on regulatory level,  when concertation and collaboration 
mechanisms are implemented,  that fmancial assistance could be envisaged at 
community level and that socio-economic aspects deserve priority attention. 
It has also to be underlined that the European countries with low populations 
would be hard pushed to fmd a national solution, but that from now on they are 
- with their counterparts of the other Member States - actors in this search for 
a solution. 
Europe cannot be satisfied with waiting for positive fallouts from incentives to 
R &  D set up in other continents, especially as the distribution of rare diseases 
can be quite variable and priorities different in every region.  The specificity of 
Industries also deserve consideration and it is one of  the aspects exploited by the 
WHO. 
Spontaneous  industrial initiatives,  either by  isolated frrms  acting alone or in 
collaboration with the WHO or other Authorities and Research Centres, or by 
groups of frrms trying to overcome difficulties and uniting their efforts, are the 
obvious  sign  of their  interest  and  their  desire  to  succeed.  They  are  the 
indicators of a positive  reaction to  well conceived and sufficiently incentive 
regulatory measures. 
What are the measures to be discussed ? 
-22-First, four "levels" will have to be considered : 
*  the Union (the Member States) and its obligation to protect Public Health; 
*  the patients, their needs and their rights; 
*  the Industry (and other research centres), its possibilities and its rights; 
*  the social institutions (state and private insurance), their obligations and/  or 
fmancing means when the product is available. 
Next, consideration will have to be given to : 
*  the fundamental research (on the diseases) and the disclosure of knowledge; 
*  research and development of new products; 
*  the development of indications of known products; 
*  the marketing of existing or abandoned products. 
The  inventory  of  measures  taken,  or  envisaged  elsewhere,  is  already 
enlightening, even if  adaptations at European level of additional initiatives or 
imaginative  solutions  could  be  beneficial.  As  a  reminder,  it  has  to  be 
mentioned: 
In Pre-Nonnative : 
•  Listing (descriptive ?) of rare diseases and an Information Centre on the state 
of research and the location of sick people (possibly with the help of  patients 
associations or of a European organisation of the same type as NORD in the 
United  States  (National  Organization  for  Rare  Disorders)  which  has  an 
impressive data base available. 
•  Epidemiological data base and determination of the frequency. 
•  List of drugs recognised as otphan, currently in use or being developed, or 
even presently used in other indications or of which the development has 
been interrupted. 
•  Complementary  studies  requested  to  IPTS  (Institute  for  Prospective  and 
Technological Studies) 
•  Determination of the criteria for admission to the status of o:rphan drug : 
character of novelty : 
-23-new drugs  (on the basis  only of the chemical structure,  or taking into 
account. the impact of minor molecular modifications ?) 
new indications 
new way of  administration of  known drugs 
panicular indications  of a  new  product under development  for other 
indications 
character of non-profitability : 
Presumption  of insufficient  ROI  (Return  on  Investment)  taking  into 
account the investment in R & D that has not succeeded as well as the one 
which had a happy ending 
frequency (prevalence) of cases : 
in absolute numbers or in percentage of the population (e.g.  < 0,1% on 
the territory of the Union which would be a less arbitrary fact the more 
so taking into account the widening of the European Union 
criteria of revocation/preservation of the status : 
if  increase in frequency 
if a  new  "clinically  superior"  therapy  is  detected,  with  - lacking  a 
definition - interpretation given to those terms 
if  the drug becomes commercially viable 
In procedural and regulatory : 
•  Dialogue with Industry (upon presumption of clinical activity) 
•  Support  (help)  in  the  development  and  the  follow-up  of experimental 
protocols 
•  Determination of the minimum content of the MA application dossier : 




-24-•  Possibility (obligation) of 
introducing, after marketing, a periodical profit/risk report 
defining the rules of pharmacovigilance applicable to these products 
•  Acceleration of the procedure (in the interest of the patient) 
•  Initial and periodical fees exemption 
In intellectual property 
•  Patent and Supplementary Protection Certificate to be adapted if  necessary . 
•  Sufficient  exclusivity  period  after  marketing  authorisation  (very  strict 
conditions to authorise the suppression of this exclusivity) 
•  Confidentiality of new data added to the dossier 
In fmancial. fiscal and economic matter : 
•  R &  D public subsidy through subsidised research programmes, 
through pooling national subsidy with community administration 
through a call to the European Development Bank 
through obtaining a budget line granted by the European Parliament 
through aids collected by patient associations 
through infonnation campaigns to the public with fund collection  ... 
•  Encouragement of  research and technical development efforts and support of 
policy towards cooperation agreements between fmns, joint-venture, merging 
of research departments, etc  .. (Art 130 F of the Treaty). 
•  Reduction of the frrm' s taxation rate 
•  Immediate deductibility of investment in R & D (on orphan drugs) 
•  Tax rebate on R & D spending 
these last three proposals to be envisaged in common with all the Member 
States 
-25-•  Levy of any tax or occasional or annual fee on the product 
•  Prices negotiated on previously defmed basis and which take into account 
particular specificities of this type of drug. 
Particular attention will have to be given in these matters in order to avoid 
the appearance  of discrimination,  protectionism,  as  well  as  the  de  facto 
invalidation  of economic  incentives  granted  to  Industry  by  subsequent, 
misplaced restrictions  of price or reimbursement in order to maintain the 
incentives to commercial success. 
In "administrative" matter 
The total or partial realisation of such initiatives  will inevitably require  the 
creation of consultation bodies,  expert committees (decision-making or not in 
highly  technical  matters),  of  administration  bodies,  even  surveillance 
committees, not counting liaison committees. 
Much caution and precision will have to be given to the allocation of the tasks 
to avoid administrative heaviness, loss of time, unnecessary costs and waste of 
work and repetitive talk. 
This is of course about the setup of a complex specific health policy for orphan 
diseases,  compatible with an industrial policy for the sector and a policy of 
stimulation of competition and suwort to the development of biotechnology. 
On the legal level, a "basic"  text (Regulation?) defming clearly the objective 
of promoting the R & D in otphan diseases and their treatment,  followed by 
execution directives or guidelines, more adaptable to the needs and experience 
would  be a  wise  proposition.  In this  way  the  fmancial  or technical  aids 
(assistance  protocols)  could  only  be  obtained  after  satisfying  a  series  of 
requirements codified by those guidelines.  Inversely, once obtained. they could 
not be questioned again or annihilated by subsequent requirements, the objective 
being to allow the sponsor to better outweigh the risk he will have to take and 
to  guarantee him a minimum of security  and continuity of the conditions in 
which he is operating. 
With the objective of obtaining a marketing  authorisation,  the Committee of 
Proprietary Medicinal Products could create a "godfather" group, capable and 
keen  to  cooperate  with  Industry,  from  the  time  of  "presumption"  of an 
interesting activity up to the fmal phase of marketing authorisation.  Moreover 
it could propose specific requirements and procedures for the orphan drugs by 
deviating, if  useful, from measures applied to other drugs. 
-26-The difficulty is to fmd,  besides the necessary  funds,  a right balance in the 
attribution of costs  between beneficiaries  (State,  Society,  Patients,  Industry) 
while keeping incentives sufficient for the effort. 
Another important problem is that incentives in the fmal phase (for instance 
marketing) such as the price, remain national prerogatives while subsidies and 
simplification of procedures which could be dealt with at community level, can 
be insufficient if  the acceptance of the principle of entitlement to a reasonable 
profit in case of success is not recognised.  In any case,  the hope for a profit 
remains  the  best  stimulation  to  research  and  competition,  itself  able  and 
necessary to control prices. 
On  the  other hand,  to  give priority  to  the  development  of already  existing 
products which are not exploited or only exploited for other indications, could 
not be favourable to obtaining rapid results. 
Europe should be sure to avoid the pitfall of  a too rigid interpretative application 
of some legal texts. 
In the field of orphan drugs, one must analyse, beyond promotion and support 
to R & D and MA, what happens or could happen at either end. At one end, the 
suspicion of a particularly interesting indication of a known product is not the 
sole  result  of know  ledge  developed  in  the  laboratory  or  during  clinical 
experimentation, but also of the information issued from the utilisation of the 
drug by the health professional.  To erect barriers to the therapeutic freedom of 
the well informed physician,  by administrative or other constraints on the use 
of drugs, can prevent the "revelation" of the orphan indication. 
At the other end, the rarity of cases and often the precarious conditions of the 
patients,  make  the  analysis  of  information  obtained  through  the 
phannacovigilance very uncertain and the benefit/risk ratio  will be set in a very 
fmely shaded context. 
With this in mind, it seems essential to plan a narrow collaboration with patients 
associations  when they exist,  even encourage them.  With them and through 
them  attempts  should  be  made  to  establish  a  much  closer  communication 
between patients and researcher.  The experimenter must be able to identify 
patients likely to participate in clinical research.  The patients as far as they are 
concerned  will  have  to  have  a  guarantee  of confidentiality  and  be  as  well 
informed as possible.  The drug under investigation can be their only chance, 
their only  hope.  On the  other hand,  the uncertainties about its  security,  its 
efficacy, secondary effects that it can generate must be explained to them.  The 
very  likely  geographical  dispersion  of the  patients  implied  in  a  clinical 
experimentation on an orphan drug, might justify to standardise the structure of 
the document by which they give their consent. 
-27-However, this analysis allows the affirmation that measures in this matter are 
indispensable,  and  that  the  duty  of Public  Health  Protection  require  them. 
Expected for a long time,  they now  have a character of urgency if the Union 
does not want to be accused of accepting dependence from abroad. 
Moreover,  these  measures  should  not be too feeble,  by fear of ending in a 
failure as well at human level as on economic level.  Patients cannot be nurtured 
with  deceptive  hopes.  Their confidence  (and  their possible participation in 
experimentation) cannot be deceived.  And, economically, subsidies, investments 
or other insufficient measures which do not allow the risk to be taken, nor the 
intensity or duration of the research effort, would be a waste. 
It is, as often the case, in the accumulation of a series of incentives and in the 
balance  achieved  between  the  different  needs,  interests  or obligations  (the 
interest of the patient remaining a priority) of the various partners that lies the 
key to the success of a project of such magnitude.  · 
In any case it would be regrettable for the European Union, for its credibility 
and for the prestige of its research industry, not to develop a series of frrst class 
measures  and  that,  in  a few  years,  the  result  of some  500 otphan products 
presently  being  developed,  would  be  scientifically  and  fmancially,  the 
prerogative only of the United States and Japan. 
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